PDB10: A METHODOLOGY TO IDENTIFY HIGH-RISK PATIENTS WITH DIABETES IN THE CALIFORNIA MEDICAID POPULATION (MEDI-CAL)  by Chaikledkaew, U et al.
330 Abstracts
PDB9
IMPACT OF AGE, GENDER,AND OUT-OF-
POCKET COSTS ON THE TIME TO
DISCONTINUATION OF ORAL ANTI-DIABETIC
AGENTS AMONG PATIENTS WITH TYPE 
2 DIABETES
Raut M, Gause D, Law AW, Sung J
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVE: This study investigated the effect of age,
gender, and out-of-pocket expenditures on medication use
and the time to discontinuation among patients with Type
2 diabetes (T2D). METHODS: Patients’ pharmacy and
medical data were obtained from a proprietary claims
database. T2D patients, 18 years and above, on oral anti-
diabetic drugs, who received beneﬁts from managed care
organizations in the year 2000 were identiﬁed. The effects
of age, gender, and co-payment on the time to medication
discontinuation were estimated. A medication was con-
sidered discontinued when the prescription was not
reﬁlled at the end of its day’s supply for an additional
50% of day’s supply. Co-payments within 1-week inter-
vals were analyzed in a time-dependent Cox regression
model to measure their impact on discontinuation.
RESULTS: Approximately 11,350 patients were identi-
ﬁed with T2D. The median co-payment per prescription
was $8.30. The time-dependent Cox regression model
showed that the risk of medication discontinuation was
8% higher for every $5 increase in co-payment [Hazard’s
ratio = 1.015]. Females had a 6% higher risk to discon-
tinuation than males (p = .04). Patients age 62 and over
have a 67% higher risk of discontinuing their medication
than patients under 61 years (p < .01). CONCLUSIONS:
Out-of-pocket prescription medication costs maybe a
potential barrier to medication persistency. Co-payment,
in addition to age and gender, signiﬁcantly impacted the
prescription discontinuation. Lack of routine and timely
care has been documented to result in a consequent trans-
fer of these costs for severe health episodes to payers. Poli-
cies intended to reduce patient non-compliance should be
supported by managed care organizations.
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OBJECTIVES: The purpose of this research is to develop
three econometric models [i.e., cost model (model #1); the
occurrence of hospitalization or ER event model (model
#2); time to hospitalization or ER event model (model
#3)] that can be used to identify high-risk patients and to
evaluate whether risk models are valid based on claims
data from the California Medicaid (MediCal) diabetic
patients. METHODS: A retrospective study was con-
ducted by using claims data from January 1995 to
December 2000. Dependent variables were total health-
care cost, the occurrence of event, and time to event.
Event included hospitalization or ER visits. Historical
data including demographic factors, healthcare cost and
utilization, type of drugs, increasing dose, adding drugs,
and changing drugs, follow-up services based on diabetic
guidelines (e.g., ofﬁce visit, lab tests, and self glucose
monitoring), medication compliance, complications, and
comorbidity were used as independent variables. The gen-
eralized estimating equation and the ﬁxed effect partial
likelihood methods were used in a longitudinal data set
and a cross-sectional data set with repeatable events,
respectively. The split sample validation method was
applied to validate the models. RESULTS: The results
show that if high-risk patients were identiﬁed by high
healthcare costs, model #1 was the most appropriate to
use since it yielded the highest percentage of correct pre-
dictions. Likewise, if high-risk patients were deﬁned as
patient who had the occurrence of hospitalization or ER
event, model #2 was the most suitable to apply. Similarly,
if high-risk patients were indicated by shorter time to hos-
pitalization or ER event, model #3 was the most proper
to utilize. Moreover, three models were valid. CON-
CLUSIONS: The choice of method depends on how 
high-risk is deﬁned by researchers or policy makers. Iden-
tiﬁcation of high-risk patients with diabetes could mean
healthcare providers and health plans could intervene to
improve patient management.
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OBJECTIVES: Proper management of type 1 diabetes
with drugs may reduce medical spending affecting the
overall healthcare expenditures. The objectives of this
